[
  {
    "ts": null,
    "headline": "Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions",
    "summary": "BOSTON, December 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with sev",
    "url": "https://finnhub.io/api/news?id=b37e132849b86a8acb6e6043af4cbf71d3a593e4c5a63878e64c5a4700037937",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765022460,
      "headline": "Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions",
      "id": 137726543,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, December 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with sev",
      "url": "https://finnhub.io/api/news?id=b37e132849b86a8acb6e6043af4cbf71d3a593e4c5a63878e64c5a4700037937"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]",
    "url": "https://finnhub.io/api/news?id=bc52093696b6b59f6be26d1592154b8348731c3f6857af29c20e123a2def2977",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764999259,
      "headline": "Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”",
      "id": 137715586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]",
      "url": "https://finnhub.io/api/news?id=bc52093696b6b59f6be26d1592154b8348731c3f6857af29c20e123a2def2977"
    }
  }
]